Virologic and immunologic response to cART by HIV-1 subtype in the CASCADE collaboration.
<h4>Background</h4>We aimed to compare rates of virologic response and CD4 changes after combination antiretroviral (cART) initiation in individuals infected with B and specific non-B HIV subtypes.<h4>Methods</h4>Using CASCADE data we analyzed HIV-RNA and CD4 counts for perso...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0071174 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849724052767244288 |
|---|---|
| author | Giota Touloumi Nikos Pantazis Marie-Laure Chaix Heiner C Bucher Robert Zangerle Anne-Marte Bakken Kran Rodolphe Thiebaut Bernard Masquelier Claudia Kucherer Antonella d'Arminio Monforte Laurence Meyer Kholoud Porter for CASCADE Collaboration in EuroCoord |
| author_facet | Giota Touloumi Nikos Pantazis Marie-Laure Chaix Heiner C Bucher Robert Zangerle Anne-Marte Bakken Kran Rodolphe Thiebaut Bernard Masquelier Claudia Kucherer Antonella d'Arminio Monforte Laurence Meyer Kholoud Porter for CASCADE Collaboration in EuroCoord |
| author_sort | Giota Touloumi |
| collection | DOAJ |
| description | <h4>Background</h4>We aimed to compare rates of virologic response and CD4 changes after combination antiretroviral (cART) initiation in individuals infected with B and specific non-B HIV subtypes.<h4>Methods</h4>Using CASCADE data we analyzed HIV-RNA and CD4 counts for persons infected ≥1996, ≥15 years of age. We used survival and longitudinal modeling to estimate probabilities of virologic response (confirmed HIV-RNA <500 c/ml), and failure (HIV-RNA>500 c/ml at 6 months or ≥1000 c/ml following response) and CD4 increase after cART initiation.<h4>Results</h4>2003 (1706 B, 142 CRF02_AG, 55 A, 53 C, 47 CRF01_AE) seroconverters were included in analysis. There was no evidence of subtype effect overall for response or failure (p = 0.075 and 0.317, respectively) although there was a suggestion that those infected with subtypes CRF01_AE and A responded sooner than those with subtype B infection [HR (95% CI):1.37 (1.01-1.86) and 1.29 (0.96-1.72), respectively]. Rates of CD4 increase were similar in all subtypes except subtype A, which tended to have lower initial, but faster long-term, increases.<h4>Conclusions</h4>Virologic and immunologic response to cART was similar across all studied subtypes but statistical power was limited by the rarity of some non-B subtypes. Current antiretroviral agents seem to have similar efficacy in subtype B and most widely encountered non-B infections in high-income countries. |
| format | Article |
| id | doaj-art-dbbff676238d46d7a24533d77b8f2e0b |
| institution | DOAJ |
| issn | 1932-6203 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-dbbff676238d46d7a24533d77b8f2e0b2025-08-20T03:10:51ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0187e7117410.1371/journal.pone.0071174Virologic and immunologic response to cART by HIV-1 subtype in the CASCADE collaboration.Giota TouloumiNikos PantazisMarie-Laure ChaixHeiner C BucherRobert ZangerleAnne-Marte Bakken KranRodolphe ThiebautBernard MasquelierClaudia KuchererAntonella d'Arminio MonforteLaurence MeyerKholoud Porterfor CASCADE Collaboration in EuroCoord<h4>Background</h4>We aimed to compare rates of virologic response and CD4 changes after combination antiretroviral (cART) initiation in individuals infected with B and specific non-B HIV subtypes.<h4>Methods</h4>Using CASCADE data we analyzed HIV-RNA and CD4 counts for persons infected ≥1996, ≥15 years of age. We used survival and longitudinal modeling to estimate probabilities of virologic response (confirmed HIV-RNA <500 c/ml), and failure (HIV-RNA>500 c/ml at 6 months or ≥1000 c/ml following response) and CD4 increase after cART initiation.<h4>Results</h4>2003 (1706 B, 142 CRF02_AG, 55 A, 53 C, 47 CRF01_AE) seroconverters were included in analysis. There was no evidence of subtype effect overall for response or failure (p = 0.075 and 0.317, respectively) although there was a suggestion that those infected with subtypes CRF01_AE and A responded sooner than those with subtype B infection [HR (95% CI):1.37 (1.01-1.86) and 1.29 (0.96-1.72), respectively]. Rates of CD4 increase were similar in all subtypes except subtype A, which tended to have lower initial, but faster long-term, increases.<h4>Conclusions</h4>Virologic and immunologic response to cART was similar across all studied subtypes but statistical power was limited by the rarity of some non-B subtypes. Current antiretroviral agents seem to have similar efficacy in subtype B and most widely encountered non-B infections in high-income countries.https://doi.org/10.1371/journal.pone.0071174 |
| spellingShingle | Giota Touloumi Nikos Pantazis Marie-Laure Chaix Heiner C Bucher Robert Zangerle Anne-Marte Bakken Kran Rodolphe Thiebaut Bernard Masquelier Claudia Kucherer Antonella d'Arminio Monforte Laurence Meyer Kholoud Porter for CASCADE Collaboration in EuroCoord Virologic and immunologic response to cART by HIV-1 subtype in the CASCADE collaboration. PLoS ONE |
| title | Virologic and immunologic response to cART by HIV-1 subtype in the CASCADE collaboration. |
| title_full | Virologic and immunologic response to cART by HIV-1 subtype in the CASCADE collaboration. |
| title_fullStr | Virologic and immunologic response to cART by HIV-1 subtype in the CASCADE collaboration. |
| title_full_unstemmed | Virologic and immunologic response to cART by HIV-1 subtype in the CASCADE collaboration. |
| title_short | Virologic and immunologic response to cART by HIV-1 subtype in the CASCADE collaboration. |
| title_sort | virologic and immunologic response to cart by hiv 1 subtype in the cascade collaboration |
| url | https://doi.org/10.1371/journal.pone.0071174 |
| work_keys_str_mv | AT giotatouloumi virologicandimmunologicresponsetocartbyhiv1subtypeinthecascadecollaboration AT nikospantazis virologicandimmunologicresponsetocartbyhiv1subtypeinthecascadecollaboration AT marielaurechaix virologicandimmunologicresponsetocartbyhiv1subtypeinthecascadecollaboration AT heinercbucher virologicandimmunologicresponsetocartbyhiv1subtypeinthecascadecollaboration AT robertzangerle virologicandimmunologicresponsetocartbyhiv1subtypeinthecascadecollaboration AT annemartebakkenkran virologicandimmunologicresponsetocartbyhiv1subtypeinthecascadecollaboration AT rodolphethiebaut virologicandimmunologicresponsetocartbyhiv1subtypeinthecascadecollaboration AT bernardmasquelier virologicandimmunologicresponsetocartbyhiv1subtypeinthecascadecollaboration AT claudiakucherer virologicandimmunologicresponsetocartbyhiv1subtypeinthecascadecollaboration AT antonelladarminiomonforte virologicandimmunologicresponsetocartbyhiv1subtypeinthecascadecollaboration AT laurencemeyer virologicandimmunologicresponsetocartbyhiv1subtypeinthecascadecollaboration AT kholoudporter virologicandimmunologicresponsetocartbyhiv1subtypeinthecascadecollaboration AT forcascadecollaborationineurocoord virologicandimmunologicresponsetocartbyhiv1subtypeinthecascadecollaboration |